InvestorsHub Logo

heysfguy

08/28/15 11:38 AM

#57714 RE: jfmcrr #57713

Here's a thought: Whatever FDA hashes out with Amarin will not be limited to the 2nd District. We've been concentrating on the jurisdictional limits of the recent ruling, but if FDA comes to some agreement with AMRN about truthful, non-misleading conduct, it would have to be considered a universal agreement. Still, I bet FDA can't do it, and it will be in the hands of the judge again.

Williams4076

08/28/15 12:13 PM

#57720 RE: jfmcrr #57713

Agree, no joint letter on PACER yet. FDA will stall this to the max. Unexpected outcome of trial...BP won't let Amarin take this alone. Amarin will gain strong marketing partner if FDA pushes to trial and IMO this will happen very quickly.... $1 Trillion in BP market cap provided amicus throughing a few billion at Amarin and selling Vascepa will be in their best interest. Could be Amgen.

BB